Abstract:

Objective To observe the effect of marvelon and mifepristone on sex hormones and perimenopausal dysfunctional uterine bleeding(PDUB) in patients with PDUB.
Methods Totally 100 cases of patients with PDUB were randomly divided into treatment group and control group. The control group was treated using mifepristone starting from the third day after diagnostic curettage, and the treatment group was treated using marvelon from the third day after diagnostic curettage. The levels of serum sex hormones, including follicle stimulating hormone(FSH), luteinizing hormone(LH) and estradiol(E₂), were detected by radioimmunoassay. The time to control of the bleeding and complete stop of bleeding in the two groups was recorded, the adverse reaction was observed. The clinical efficacy was evaluated at the end of follow-up.
Results The total clinical effective rate of the marvelon group was 98.0%, which was significantly higher than that of the control group(88.0%)(P<0.05). After treatment, the FSH, LH and E2 levels of the treatment group significantly decreased compared with the control group(P<0.05); The FSH, LH and E₂ levels of the control group between the prior-treatment and posttreatment was no significant difference(P>0.05); After treatment, the thickness of endometrium of the treatment group was(4.04±0.41) mm, that of the control group was(6.69±0.78) mm, the difference was significant(P<0.05). After treatment, the endometrium of the treatment group was normal, while in control group the endometrium of 11 cases still had simple hyperplasia, the pathological results of the two groups were significantly different(P<0.05). There was no obvious adverse reaction in the two groups.
Conclusion The marvelon in treatment of PDUB can inhibit the release of serum FSH, and prompt the declining of endogenous E₂ and LH. It is effective, safe, reliable and worthy of clinical application.

Key words: marvelon, mifepristone, dysfunctional bleeding, peri-menopausal, sex hormone